Cesar Augusto Nunez

Medicine & Life Sciences

1. Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
2. Pediatrics 93%
3. venetoclax 84%
4. blinatumomab 46%
5. B-Lymphocytes 45%
6. Leukemia 35%
7. B-Lymphoid Precursor Cells 35%
8. Acute Myeloid Leukemia 35%
9. Dendritic Cells 35%
10. Child 34%
11. Bone Marrow 30%
12. Transplants 27%
13. Chimeric Antigen Receptors 25%
14. tisagenlecleucel 24%
15. Complementarity Determining Regions 24%
16. Inotuzumab Ozogamicin 24%
17. T-Lymphocytes 24%
18. Surrogate Immunoglobulin Light Chains 24%
19. VDJ Recombinases 23%
20. Neoplasms 22%
21. tazobactam drug combination ceftolozane 22%
22. Immunoglobulin Genes 22%
23. Young Adult 21%
24. Lymphomatoid Papulosis 21%
25. Leukemia, Myelomonocytic, Acute 20%
26. Leukemia, Monocytic, Acute 19%
27. Therapeutics 19%
28. Antibodies 18%
29. Recurrence 18%
30. Anthracyclines 17%
31. Residual Neoplasm 17%
32. Immunotherapy 17%
33. Lymphoproliferative Disorders 17%
34. Respiratory Syncytial Virus Infections 17%
35. Decitabine 17%
36. fludarabine 17%
37. Interleukin-7 17%
38. Philadelphia Chromosome 17%
39. Unrelated Donors 16%
40. Systemic Inflammatory Response Syndrome 16%
41. Pseudomonas Infections 16%
42. Fetal Blood 16%
43. Clinical Trials, Phase I 16%
44. Immunoglobulin M 15%
45. DNA Nucleotidylexotransferase 15%
46. Fetus 15%
47. T-Cell Lymphoma 15%
48. Drug Therapy 15%
49. Cell- and Tissue-Based Therapy 15%
50. Cardiotoxicity 15%